Decapeptyl® SR 3mg & Decapeptyl® SR 11.25mg
triptorelin
Description
Decapeptyl® SR 3mg Triptorelin (I.N.N.) 4.2 mg, as triptorelin acetate. Powder for suspension for injection, sustained release formulation.
Decapeptyl® SR 11.25mg Triptorelin (I.N.N.) 15 mg, as triptorelin acetate. Powder for suspension for injection, sustained release formulation.
Active substance
Triptorelin
Indications
Decapeptyl® SR 3mg is indicated for:
- Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
- Treatment of metastatic prostate cancer.
- Treatment of endometriosis.
- Treatment of uterine fibroids prior to surgery or when surgery is not appropriate.
Decapeptyl® SR 11.25mg is indicated for:
- Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
- Treatment of metastatic prostate cancer.
- Treatment of endometriosis.
- Treatment of precocious puberty (onset before 8 years in girls and 9 years in boys).
Further information
Information for UK Healthcare Professionals
Decapeptyl SR 3mg Summary of product characteristics
Decapeptyl SR 3mg Patient information leaflet
